AKT2 and triple-negative breast carcinoma: When delivering RAC-beta serine/threonine protein kinase (AKT2) siRNA and p53 plasmid DNA using bola4A and bola8A, respectively, effective anticancer activity and therapeutic effects were achieved in mouse models of ovarian and cervical cancer xenografts (SKOV-3 and HeLa), as well as lung metastasis models induced by triple negative breast cancer (4T1) and melanoma (B16-F10) in mice.